Straumann's Ownership of Two Different Brands in the Dental Implant Business: Strategic Advantage or Lack of Focus? Custom Case Solution & Analysis

Evidence Brief

Financial Metrics

• Revenue Performance: Straumann reported total net sales of 718 million CHF in 2014. This represented a 4 percent organic growth rate compared to the previous year (Exhibit 1).
• Market Valuation: The value segment of the dental implant market grew at a rate of 10 to 15 percent, significantly outpacing the premium segment which grew at 0 to 5 percent (Paragraph 8).
• Acquisition Cost: The organization increased its stake in Neodent to 100 percent in 2015 for a total consideration of approximately 680 million CHF (Paragraph 12).
• Regional Contribution: Emerging markets, specifically Latin America, accounted for a growing share of the total market, with Neodent holding a 40 percent market share in Brazil (Paragraph 14).

Operational Facts

• Manufacturing Footprint: Straumann maintains high-precision manufacturing in Villeret, Switzerland. Neodent operates production facilities in Curitiba, Brazil, focused on cost-efficient output (Paragraph 15).
• Product Portfolio: The Straumann brand focuses on the Roxolid and SLActive technologies. Neodent focuses on the Grand Morse and Drive systems which target the value-conscious segment (Paragraph 18).
• Distribution: The premium brand utilizes a direct sales force in 20 countries. The value brands utilize a mix of direct sales and third-party distributors depending on the region (Paragraph 20).

Stakeholder Positions

• Marco Gadola (CEO): Advocated for the multi-brand strategy to capture the growing group of general practitioners who are price-sensitive (Paragraph 22).
• Gilbert Achermann (Chairman): Supported the move toward a broader market presence while emphasizing the need to protect the Swiss brand heritage (Paragraph 23).
• General Practitioners (GPs): This group increasingly performs implant procedures but lacks the specialized training of periodontists, leading them to prioritize simplicity and lower costs (Paragraph 25).

Information Gaps

• Cannibalization Data: The case does not provide specific figures on the number of existing Straumann customers who switched to Neodent after the acquisition.
• Margin Comparison: Explicit gross margin percentages for the Neodent product line versus the Straumann product line are not disclosed.
• R and D Allocation: The exact split of research and development spending between the premium and value brands is missing.

Strategic Analysis

Core Strategic Question

• How can the organization dominate the high-growth value segment through Neodent without diluting the premium brand equity and technical prestige of the Straumann parent brand?

Structural Analysis

The dental implant industry is undergoing a fundamental change. The Five Forces analysis reveals that the bargaining power of buyers is increasing as general practitioners enter the market. These buyers are less brand-loyal than specialists and more focused on the economic return of the procedure. The threat of new entrants is high, particularly from Asian manufacturers like Osstem and Dentium, who use lower price points to gain share. The structural problem is that the premium segment is maturing, while the value segment is commoditizing rapidly.

Strategic Options

Option 1: Independent Silo Management

• Rationale: Maintain complete separation between Straumann and Neodent in sales, marketing, and clinical education to prevent brand bleed.
• Trade-offs: High operational costs due to duplicated functions and missed opportunities for backend integration.
• Requirements: Separate regional headquarters and distinct supply chains.

Option 2: The Multi-Brand Platform Model

• Rationale: Integrate backend operations such as manufacturing, IT, and logistics while maintaining distinct customer-facing identities.
• Trade-offs: Risk of internal friction and cultural clashes between the high-cost Swiss culture and the low-cost Brazilian culture.
• Requirements: A unified global supply chain and a shared digital platform for order management.

Option 3: Selective Brand Migration

• Rationale: Use Neodent as the primary vehicle for all emerging markets and move the Straumann brand to a purely high-end clinical specialty niche.
• Trade-offs: Potential loss of revenue in developed markets where some GPs might still prefer a premium brand if priced correctly.
• Requirements: Significant rebranding efforts and a shift in sales force incentives.

Preliminary Recommendation

The organization should pursue Option 2. The multi-brand platform model allows the company to benefit from scale in purchasing and logistics while protecting the premium price floor of the Straumann brand. This approach directly counters the threat from Asian competitors by providing a low-cost alternative backed by Swiss quality assurance. Success depends on maintaining a strict firewall between the two sales teams to ensure that a single sales representative never offers both brands to the same customer.

Implementation Planning

Critical Path

• Phase 1 (Months 1-3): Establish the Institutional Business Unit to house all non-premium brands. This provides a clear organizational structure that separates value-based decision-making from premium brand management.
• Phase 2 (Months 4-6): Integrate the global logistics network. Transition Neodent distribution in North America and Europe to the existing Straumann warehouses to reduce lead times and shipping costs.
• Phase 3 (Months 7-12): Launch the Medentika and Neodent joint value proposition in key European markets. Train a dedicated value sales force that does not overlap with the premium team.

Key Constraints

• Sales Force Conflict: The primary constraint is the potential for the sales teams to compete for the same dental accounts. If not managed, this lead to internal price wars.
• Regulatory Approval: Expanding the Neodent product line into new geographies requires sequential regulatory filings which can delay the rollout by 12 to 18 months in some regions.

Risk-Adjusted Implementation Strategy

Execution will focus on a geographic phased approach. The organization will first deploy the dual-brand strategy in markets with high GP penetration, such as the United States and Spain. To mitigate the risk of brand dilution, all Neodent packaging and marketing materials will remain distinct, with no mention of the Straumann name in patient-facing literature. A contingency plan is in place to revert to independent distribution if cannibalization of the premium brand exceeds 5 percent in any single quarter.

Executive Review and BLUF

BLUF

The acquisition of Neodent is a necessary defensive and offensive move. The dental implant market is bifurcating. Staying exclusively in the premium segment is a recipe for long-term irrelevance as general practitioners become the primary customers. The dual-brand strategy is the only way to capture the 15 percent growth in the value segment while maintaining the 70 percent gross margins of the premium business. The organization must accept that some cannibalization is inevitable but preferable to losing the customer to a third-party competitor. The verdict is: APPROVED FOR LEADERSHIP REVIEW.

Dangerous Assumption

The most dangerous assumption is that the clinical superiority of the Straumann brand will continue to command a 200 percent price premium as the technology becomes standardized. If the clinical outcomes between a 200 dollar implant and a 600 dollar implant remain indistinguishable in 95 percent of cases, the premium brand will collapse regardless of the dual-brand strategy.

Unaddressed Risks

• Cultural Integration: The risk of talent attrition at Neodent is high if the Swiss management style imposes too much bureaucracy on the entrepreneurial Brazilian team. Probability: High. Consequence: Loss of market leadership in Latin America.
• Pricing Transparency: In a digital age, customers will discover the shared ownership. If they perceive the products as identical with different labels, the price floor for Straumann will evaporate. Probability: Moderate. Consequence: Rapid margin compression across the entire portfolio.

Unconsidered Alternative

The team did not fully evaluate a white-label strategy. Instead of owning and operating a second brand, the organization could have manufactured private-label implants for large dental service organizations. This would have captured the volume of the value segment without any direct association or brand risk to the Straumann name.

MECE Analysis of Market Segments

• Premium Segment: Specialists, complex cases, high clinical evidence requirements, high price.
• Value Segment: General practitioners, standard cases, reliable performance, moderate price.
• Discount Segment: Price-only buyers, basic cases, minimal service, lowest price.